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Phage-display methodology has been used to select variant CD4 proteins exhibiting increased binding to the surface
envelope glycoprotein, gp120, of Human Immunodeficiency Virus Type-1. To facilitate the selection, a library of mutant CD4
proteins was constructed by cloning a PCR-generated error prone population of the first two domains of CD4 into the
phagemid expression vector pHEN1. Phage displaying CD4 in functional form were confirmed by Western blot with CD4-
specific antibody and by phage ELISA on immobilized gp120. Biopanning of CD4 phage on immobilized gp120 followed by
individual characterization identified five clones with increased binding to gp120. All of the selected variants had one or
two amino acid substitutions within the V1 domain of CD4, notably at positions 15, 27, 30, 50, and 66 located in the strands
surrounding the main binding loop. Variants which exhibited increased binding to recombinant gp120 in vitro were also
shown to have an increased capacity for virus neutralization broadly in line with their in vitro binding activity. q 1997 Academic
Press
INTRODUCTION bind and neutralize primary virus isolates may be re-
quired if this form of therapy is to be pursued. A dissec-
The interaction between Human Immunodeficiency Vi- tion of the role of individual residues in the V1 domain
rus type 1 (HIV-1) envelope glycoprotein gp120 with the in gp120 binding, based on the available structure, has
cellular receptor CD4 is the initial event in the infection found that certain amino acids in the CDR2 loop, notably
process (Dalgleish et al., 1984; Klatzmann et al., 1984). Phe43, Lys46, and Arg59, are critical for gp120 binding
This binding can be mimicked in vitro using soluble anti- (Moebius et al., 1992). In addition, Alanine scanning mu-
gens and occurs with high affinity, Ka 109 mol01 (Moore, tagenesis has demonstrated that, while most substitu-
1990; Moore et al., 1990). CD4 is a transmembrane pro- tions in V1 result in a lower affinity of binding, certain
tein with four extracellular immunoglobulin-like domains amino acid changes can improve the binding affinity
(Maddon et al., 1985) and mapping of the residues in- (Ashkenazi et al., 1990).
volved in contacting gp120 has located the binding site In this demonstration study we show that phage dis-
to a region in the amino terminal domain with sequence play of the human CD4 V1 sequence results in phage
homology to the immunoglobulin CDR-II sequence (Clay- capable of binding gp120 and that variants can be se-
ton et al., 1988; Arthos et al., 1989; Brodsky et al., 1990). lected by multiple rounds of panning with increased bind-
The structure of the external two domains of CD4 (V1 ing to gp120. All variants isolated by this approach had
and V2) has been determined (Ryu et al., 1990; Wang et changes in the b-strands surrounding the gp120 binding
al., 1990) and has shown the gp120 binding site to be a site consistent with this region determining this high af-
distinct loop (the C’C’’ loop) projecting from the upper finity interaction. Moreover, the ability of the variant CD4
side of the V1 domain. Substitution of this loop onto the molecules to bind recombinant gp120 more strongly in
otherwise unrelated rat CD4 molecule restores the ability soluble assays was associated with an increased poten-
of gp120 to bind (Schockmel et al., 1992). Soluble CD4 tial when compared to the wild-type sequence to neutral-
(sCD4) effectively neutralizes HIV-1 in vitro (Fisher et al., ize HIV infectivity.
1988; Clapham et al., 1989; Ward et al., 1991) but inhibi-
tion does not extend to primary isolates (Daar et al., 1990) MATERIALS AND METHODS
possibly as a result of spike conformation on the virion
Vectors for CD4 expressionsurface (Moore and Sweet, 1993). This data suggests
that new forms of CD4, selected for increased affinity to To create the libraries of CD4 mutants, CD4 DNA frag-
ments comprising the V1 or V1/V2 domains were ampli-
fied from cDNA using the polymerase chain reaction1 To whom correspondence and reprint requests should be ad-
dressed. E-mail: ijones@molbiol.ox.ac.uk. (PCR) with primers that incorporated restriction sites for
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cloning CD4 in frame between the PstI and XhoI sites of phage for isolation of individual mutants or for regrowth
of the library prior to subsequent rounds of panning.the phagemid expression vector pHEN1 (Hoogenboom
et al., 1991). The CD4 sequence was positioned behind
Phage-ELISAa PelB leader sequence to promote transport to the per-
iplasmic space and fused at the C terminus to the N- ELISA plates (MaxiSorp, Nunc) were coated as for bio-
terminus of pIII envelope protein of bacteriophage fd. panning with 0.1 ml of gp120 solution for 8 hr at room
Following selection and characterization, mutant CD4 temperature, blocked with 5% milk in PBS for 1 hr, and
molecules were expressed at a higher level by transfer washed three times with PBS. Then 0.1 ml of each
into the pET25b(/) vector (Novagen) to produce a CD4 phagemid preparation at 1011 PFU/ml was applied to
protein ‘‘tagged’’ at the carboxy terminus with a Herpes the 1st well in 3% dried milk–PBS and a dilution series
Simplex Virus (HSV) epitope for immunological detection made in the same buffer. After overnight incubation at
and relative quantitation. room temperature wells were washed four times with
PBS and a sheep polyclonal anti-M13 antibody (Phar-
Mutagenesis of CD4 and construction of phage- macia Biotech) was applied as a 1 mg/ml solution in
display libraries 3% dried milk–PBS. After a 1-hr incubation followed by
washing, an anti-sheep alkaline phosphatase conjugatePoint mutations to substitute both Arginine 58 and Ar-
(Sigma) in 3% milk–PBS was added for 1 hr. Wells wereginine 59 for Alanine in the CD4 protein (mutant RR) were
then washed four times with TBS and the color reactionintroduced by overlap extension site-directed mutagene-
developed with an AMPAK kit (DAKO). The assay wassis (Winter et al., 1994) using the following primers pairs.
commonly carried out in triplicate to allow for variationsWH6F: GCGGCCCAGCCGGCCATGGCCCAG (forward)
in the preparation of phage and the relative loading ofand CD4RR2: GTCCCAAAGGCTTGCTGCTGAGTCAGC-
CD4-pIII molecules per virion.GCG (reverse) and CD4RR1: CGCGCTGACTCAGCAGCA-
AGCCTTTGGGAC (forward) and WH6R:GCGTTGTTC-
Neutralization assayTGCGGCCGCCCGTTT (reverse). The two fragments,
each containing one mutation, were annealed and sub- Neutralization of the HIV BH10 molecular clone was as-
jected to a final round of PCR using WH6F and WH6R sessed using the C8166 cell line as target cells with
before being cloned into the pHEN1 vector. determination of p24 antigen production as the end-point
Libraries of mutant CD4s were generated by redun- as reported previously (McKeating et al., 1991). Wild-type
dant PCR using both wild-type CD4 V1 and CD4 mutant and CD4 variants were incubated at 377 for 1 hr with an
RR as template. DNA was amplified using WH6F and 6R equal volume of virus (in triplicate using three different
primers, and an aliquot of the reaction mixture diluted virus dilution, 1:5, 1:25, and 1:125). Following the virus/
106 times to provide a template for a second PCR reac- CD4 incubation 10,000 cells in a final volume of 75 ml
tion. The dilution and reamplification was repeated for a RPMI, 10% FCS were added. Cells were washed on Days
third round before all three reactions were combined, 1 and 3, by centrifugation, and refed. Seven days postin-
ligated into the pHEN1 vector, and used for electropora- fection the 50% infectious dose (ID50) of the virus stock
tion of E. coli TG1 cells. Random analysis of the library was determined in parallel, and the neutralization assay
showed that 50% of the final population contained at was evaluated for virus dilutions containing 100 ID50 .
least one base substitution in the CD4 sequence. Neutralization was defined as the ability to inhibit virus
replication by 50 and 90% as assessed by p24 antigen
Biopanning production, where the sensitivity of the p24 antigen assay
is 3 pg/50 ml and the error between assays was in theThe rescue of phagemid libraries, preparation of
order of 15%.phagemid particles, and panning in ‘‘immuno’’ tubes were
performed as previously described (Hoogenboom et al.,
CD4-ELISA
1991). Briefly, polystyrene tubes (LIP Ltd.) were coated
overnight at room temperature with 1 ml of 4 mg/ml bacu- The CD4 fragments rescued from the selected phage
were transferred into the pET25b vector and expressedlovirus-produced HIV IIIB/LAI gp120 solution in 0.2 M
NaHCO3 , blocked with 5% dry milk in PBS for 6 hr at in E. coli strain BL21(DE3) (Novagen). E. coli cultures
were induced by 1 mM IPTG at OD600  0.6 and incu-room temperature and washed 5 times with PBS. One
milliliter of the CD4 phagemid library at 1012 PFU/ml bated either overnight (for the CD4 secretion into culture
medium) or for 4 hr at 377 with shaking (for extractionwas applied in 3% milk-PBS and incubated overnight at
room temperature. The tubes were washed eight times from the periplasm). Extraction of the protein from the
periplasm was carried out by cold osmotic shock. Coat-with PBS, and the bound phagemid particles were eluted
with 1 ml of 0.1 M triethanolamine, which was neutralized ing, blocking, and processing of ELISA plates was as
described for phage-ELISA except that an anti-HSV mu-immediately with 1 ml of 1 M Tris–HCL, pH 7.4. Esche-
richia coli TG1 cells were infected with the recovered rine monoclonal antibody (MAb) (Novagen) was used for
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FIG. 3. Binding of soluble mutant CD4s to gp120. CD4 mutant se-
quences isolated by phage display were transferred to pET vectors for
higher levels of expression and were extracted from the E. coli per-
iplasm as described. The relative CD4 concentration was determined
by using anti-HSV tag MAb binding using a protein of known concentra-
tion containing the HSV-tag as a control (Novagen). The lanes wereFIG. 1. A schematic of the cloning and selection methodology used
(l) V2; (s) RR; (*) 22; (m) D11; (.) E6; (j) F8; ( ) B6.for the selection of CD4 molecules with increased gp120 binding.
detection. After 1 hr the plates were washed four times aware that the interaction between wild-type CD4 and
with PBS, incubated for 1 hr with an anti-mouse alkaline gp120 molecules was already strong and that selection
phosphatase conjugate (Sigma) at 1:1000 dilution, and above this level may be inefficient. Therefore, we mutated
developed with AMPAK (DAKO) as before. the starting CD4 population to reduce the initial binding
affinity, arguing that any reversion events may be accom-RESULTS
panied by changes that improved binding beyond the
In considering strategies for the isolation of variant wild-type level. It has been shown previously that the
CD4 proteins with improved gp120 binding we were Arginine residues at positions 58 and 59 within the V1
domain were essential for interaction with gp120 (Moe-
bius et al., 1992); thus, both of these residues were mu-
tated to Alanine in the context of a V1/ V2 CD4 construct
to form the mutant ‘‘RR’’ as the starting molecule for the
mutagenesis studies. CD4-RR was unable to bind gp120
in the assays tested (data not shown) and was used as
a knockout control in subsequent binding and neutraliza-
tion experiments.
To produce a library of CD4 mutations, three rounds
of redundant PCR were performed using DNA from both
the mutant RR template (V1 / V2) and a wild-type tem-
plate (V1). Amplified material from each round was
pooled and ligated into the phagemid expression vector
pHEN1 to display a library of mixed V1 and V1 / V2
domain mutant CD4s on the phage surface. Phage librar-
ies were subjected to 5 rounds of biopanning on purified
FIG. 2. Phage-ELISA of individual clones picked after 5 rounds of gp120 immobilized on a solid support (Morikawa et al.,
panning. Phage stocks were prepared from each CD4 clone by infection
1990) following the general regime shown in Fig. 1.with helper phage and titered to give an estimation of CD4 concentra-
Phagemids eluted from the panning reaction were propa-tion although no direct measure was taken of the level of CD4 incorpo-
ration into phage at this stage. They were applied to immobilized gp120 gated as single clones in TG1 cells and their ability to
at 1011 PFU/ml in the 1st well followed by serial twofold dilutions. After bind to gp120 confirmed by phage ELISA compared to
incubation overnight at room temperature bound phage was detected the wild-type CD4 and mutant RR. A total of 101 E. coli
using an antibody to the phage coat protein. The lanes were (l) V2;
TG1 clones were picked at random after the 5th round(s) RR; (*) 22; (m) D11; (.) E6; (j) F8; ( ) B6. The error bar (top right)
of selection and subjected to a second round of charac-derives from the maximum variance seen between the same samples
when the experiment was run in triplicate. terization in which the phage from each colony were
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TABLE 1 the phage surface and the reproducibility of the assays
were also improved. All five mutants showed an increaseNeutralization of HIV-1 by CD4 Variants
in gp120 binding compared to the wild-type CD4 V1 /
CD4 variant ID90 (mg/ml) ID50 (mg/ml) V2 control (Fig.3), suggesting that the acquired changes
affected the gp120 binding site directly rather than being
V2 NRa 1.0 dependent on a conformational effect on the V1 domain
RR NR NR
in the context of a phage pIII protein fusion although for22 (D11) NR 0.5
one mutant, F8, this was relatively less apparent.E6 NR 0.6
F8 NR 1.0 Soluble wt and variant CD4 preparations were assayed
B6 0.5 0.2 for their ability to neutralize the molecular clone HXB10
(the same sequence as the recombinant gp120 useda NR, not reached.
for biopanning). Neutralization measures recognition of
membrane bound oligomeric forms of Env gp120 in asso-
ciation with gp41 and has the potential to detect differ-screened directly for binding to gp120 by phage ELISA.
ences when compared to the soluble assays. In the main,Five clones from this screen showed increased binding
the pattern of neutralization observed correlated broadlyfor gp120 when compared to the parental CD4 control
with the gp120 binding activities of each variant in the(Fig. 2). The origin of the DNA from the five clones was
CD4-ELISA assay although there were minor exceptionsdetermined by PCR using domain-specific primers. Vari-
reflecting the different parameters measured by eachants E6 and B6, originated from the library of mutagen-
assay (Table 1). Variant B6 was most efficient at neutraliz-ized V1 fragments while clones 22, F8, and D11 origi-
ing HIV-1 and also demonstrated the greatest binding tonated from the RR V1 / V2 library.
recombinant gp120 by ELISA (cf. Figs. 2 and 3). IsolatesAlthough phage ELISA provided a rapid screen for the
E6 and 22 provided a moderate improvement in neutral-identification of CD4 variants that had regained gp120
ization while CD4-F8 was the same as the wild-type con-binding ability, their absolute accuracy in our hands var-
trol despite exhibiting an increased binding. Knockoutied from experiment to experiment possibly due to the
mutant RR had no detectable ability to inhibit infectivity.variable pickup of the pIII-CD4 molecules on the phage
All CD4 variant constructs were sequenced to identifysurface. Therefore, to provide soluble antigen whose
the amino acid changes responsible for the observedbinding could be quantitated more accurately, soluble
phenotypes. No changes were located within the se-variant CD4 was produced from each of the mutants
quences previously reported to be in direct contact withidentified in the first screen by recloning into the pET25b
gp120 (Brand et al., 1995). Each variant generated fromprokaryotic expression system (Novagen). Use of this
the knockout mutant RR library demonstrated that thevector facilitated detection and relative quantitation of
Alanine substitutions had reverted to Arginine, confirm-the proteins by ‘‘tagging’’ the C-terminus with a HSV pep-
ing reports that the Arg duplet is essential for gp120tide to allow their immune detection. CD4 proteins were
binding (Ashkenazi et al., 1990). Clones 22 and D11 werereleased from induced cells after overnight growth and
identical and exhibited Asn30/Asp and Lys50/Argwere assayed for gp120 binding by ELISA. Soluble pro-
changes. Clone E6 had Thr15/Ala, while clone F8 demon-tein prepared in this way had similar relative binding
characteristics to the equivalent sequence expressed on strated His27/Tyr and clone B6 Asn66/Ser (Fig. 4). All of
FIG. 4. Sequence alignments of the mutants selected by panning and phage ELISA. The sequence of the V1 / V2 region was determined for
each mutant but changes were found in the V1 domain only. The wild-type CD4 sequence is shown from residues 10–100 only.
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FIG. 5. Location of the CD4 mutants selected by phage display in the 3-dimensional structure of the CD4 V1 domain. Coordinates for the rendering
were taken from the Brookhaven database file 1CD4 and displayed using Rasmol version 2.6 (Roger Sayle). Each mutation has been indicated and
the CDR2 loop thought to interact directly with gp120 is highlighted by the dotted line.
the mutations were located within the first half of the V1 had an amino acid change within this region (Lys50),
while a second had a change (Asn30) located near thedomain and were scattered throughout the CDR-1- and
bottom of the CDR2 loop (Fig. 5). Of the remaining vari-CDR-2-like regions that essentially flank the C’C’’ loop in
ants, F8 had a substitution (His27) in the b-sheet surfacedirect contact with gp120.
adjacent to the 38–59 region, while variants E6 and B6
had changes (Thr15 and Asn66, respectively) located inDISCUSSION
a part of the b-sheet structure that is quite distant from
It was suggested originally, based on the CD4 atomic the region of exposed residues in direct contact with
structure and mutagenesis studies, that residues be- gp120.
tween positions 38 and 59 in the CD4 molecule, the loop Most of the CD4 mutants published to date have re-
analogous to the Ig CDR2 loop, were involved in direct corded a negative influence of the majority of amino acid
interaction with gp120 (Wang et al., 1990). Within this substitutions on the gp120–CD4 binding interaction (e.g.,
region, some residues such as Phe43 and Arg59 were Ashkenazi et al., 1990). This may, in part, reflect the meth-
shown to be essential for gp120 binding while other odology employed by most studies in which, for each
nonessential residues such as Lys35 and Lys46 were oligonucleotide-directed mutation made, expression of
concluded to moderate binding somewhat (Moebius et CD4 and assessment of gp120 binding was performed
al., 1992; Moore and Sweet, 1993; Choe and Sodroski, for each variant, limiting the number of mutants that could
be examined. A random methodology designed to facili-1995). In this study, only one selected variant, clone 22,
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tate screening of a library of mutated CD4 sequences tions at residues 66 and 15 (variants B6 and E6) which
are more distant from the C’C’’ region are more difficulthas been reported (Tsui et al., 1992) based on binding
to gp120 where individual mutants were immobilized on to interpret but suggest that changes distinct from the
binding site can modulate binding activity. No isolatednitrocellulose filters. However, given that the frequency
of variants demonstrating increased affinity for gp120 variants retained the double Arg/Ala markers at residues
58 and 59 introduced to facilitate the selection of im-may be very low, this method also has limitations in the
number of clones which can be analyzed. To overcome proved binding variants reflecting the importance of
these residues for CD4 function and suggesting thatthis limitation, biopanning of phage CD4 enabled us to
enrich for a library of variant CD4 proteins with increased compensatory mutations elsewhere in the molecule may
not be possible.gp120 binding. In this approach the size of a library that
can be screened is limited only by the efficiency of liga- The ability to select for CD4 variants with increased
binding to gp120 suggests that it may be possible totion and E. coli electroporation and the entire pool of
mutant molecules may be used for each round of biopan- select for CD4 molecules with increased potency to neu-
tralize divergent primary HIV isolates by biopanning mu-ning allowing the selection of CD4 variants from a very
low initial frequency. This approach allowed the selection tant CD4 libraries on immobilized virus. Primary viruses
are relatively resistant to CD4-mediated neutralizationof novel amino acid substitutions not identified to date
in previous studies. The substitution observed in variant limiting the therapeutic use of CD4 (Daar et al., 1990;
Moore et al., 1992; Orloff et al., 1993). However, the use22 is in the same position as a previously described
mutation (Arthos et al., 1989; Ashkenazi et al., 1990; Moe- of phage-display technology may enable the selection of
CD4 variants which more effectively neutralize primarybius et al., 1992); however, while His27/Tyr led to an
increased binding to gp120, substitution of His27/Ala isolates or provide specific reagents for probing the
oligomeric organization of the envelope on the virion sur-was previously reported to weaken this interaction
(Arthos et al., 1989; Ashkenazi et al., 1990). Similarly, the face.
substitution of Asn66/Ser observed in variant B6 led to
an increase in binding of CD4 while Asn66/Lys had no ACKNOWLEDGMENTS
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